OMG

Oligodendrocyte-myelin glycoprotein (OMGP), also termed OMG, is a glycosylphosphatidylinositol-anchored cell adhesion molecule expressed in the central nervous system. Composed of eight leucine-rich repeats (LRRs), it facilitates myelination by interacting with neuronal receptors such as NgR, which regulates axonal growth and regeneration. OMGP stabilizes myelin sheaths and modulates interactions between oligodendrocytes and axons, contributing to efficient neural signal transmission.
Dysregulation of OMGP is implicated in demyelinating disorders like multiple sclerosis, where impaired myelin repair exacerbates neurological deficits. Recent studies highlight its LRR domains as therapeutic targets: deleting specific regions (e.g., LRR181-228) disrupts its inhibitory effect on neuroregeneration, suggesting potential for promoting remyelination. Experimental approaches, including monoclonal antibodies and peptide mimics, aim to restore OMGP balance and enhance recovery in preclinical models, though clinical translation remains ongoing.